Grape King Bio Ltd Asset Resilience Ratio
Grape King Bio Ltd asset resilience ratio. Grape King Bio Ltd (1707) has an Asset Resilience Ratio of 1.09% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 1707 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Grape King Bio Ltd (2002–2025)
Asset resilience ratio of Grape King Bio Ltd from 2002 to 2025. This chart shows how Grape King Bio Ltd's Asset Resilience Ratio has changed over time. Read Grape King Bio Ltd (1707) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Grape King Bio Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Grape King Bio Ltd assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$163.72 Million | 1.09% |
| Total Liquid Assets | NT$163.72 Million | 1.09% |
Asset Resilience Insights
- Limited Liquidity: Grape King Bio Ltd maintains only 1.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Grape King Bio Ltd Industry Peers by Asset Resilience Ratio
Compare Grape King Bio Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Grape King Bio Ltd Asset Resilience Ratio by Year (2002–2025)
Grape King Bio Ltd asset resilience ratio by year from 2002 to 2025. The table below shows the annual Asset Resilience Ratio data for Grape King Bio Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.72% | NT$113.04 Million ≈ $3.56 Million |
NT$15.74 Billion ≈ $495.84 Million |
+0.13pp |
| 2024-12-31 | 0.58% | NT$89.41 Million ≈ $2.82 Million |
NT$15.32 Billion ≈ $482.78 Million |
-0.39pp |
| 2023-12-31 | 0.97% | NT$151.21 Million ≈ $4.76 Million |
NT$15.51 Billion ≈ $488.71 Million |
+0.20pp |
| 2022-12-31 | 0.78% | NT$117.05 Million ≈ $3.69 Million |
NT$15.05 Billion ≈ $474.25 Million |
-1.09pp |
| 2021-12-31 | 1.87% | NT$262.24 Million ≈ $8.26 Million |
NT$14.06 Billion ≈ $442.99 Million |
+1.27pp |
| 2020-12-31 | 0.59% | NT$77.66 Million ≈ $2.45 Million |
NT$13.10 Billion ≈ $412.85 Million |
-0.16pp |
| 2019-12-31 | 0.76% | NT$85.82 Million ≈ $2.70 Million |
NT$11.36 Billion ≈ $357.87 Million |
+0.40pp |
| 2018-12-31 | 0.36% | NT$38.21 Million ≈ $1.20 Million |
NT$10.65 Billion ≈ $335.47 Million |
-2.17pp |
| 2017-12-31 | 2.53% | NT$250.45 Million ≈ $7.89 Million |
NT$9.89 Billion ≈ $311.64 Million |
-1.55pp |
| 2016-12-31 | 4.08% | NT$389.45 Million ≈ $12.27 Million |
NT$9.55 Billion ≈ $300.87 Million |
-4.36pp |
| 2015-12-31 | 8.44% | NT$726.59 Million ≈ $22.89 Million |
NT$8.61 Billion ≈ $271.34 Million |
+4.60pp |
| 2014-12-31 | 3.84% | NT$205.97 Million ≈ $6.49 Million |
NT$5.37 Billion ≈ $169.15 Million |
-5.32pp |
| 2013-12-31 | 9.16% | NT$423.81 Million ≈ $13.35 Million |
NT$4.63 Billion ≈ $145.83 Million |
-1.58pp |
| 2012-12-31 | 10.74% | NT$415.31 Million ≈ $13.08 Million |
NT$3.87 Billion ≈ $121.87 Million |
+1.99pp |
| 2011-12-31 | 8.74% | NT$302.13 Million ≈ $9.52 Million |
NT$3.46 Billion ≈ $108.87 Million |
-0.12pp |
| 2010-12-31 | 8.86% | NT$283.78 Million ≈ $8.94 Million |
NT$3.20 Billion ≈ $100.86 Million |
-11.98pp |
| 2009-12-31 | 20.85% | NT$668.14 Million ≈ $21.05 Million |
NT$3.21 Billion ≈ $100.98 Million |
-1.26pp |
| 2008-12-31 | 22.10% | NT$571.49 Million ≈ $18.01 Million |
NT$2.59 Billion ≈ $81.47 Million |
-1.76pp |
| 2007-12-31 | 23.86% | NT$602.68 Million ≈ $18.99 Million |
NT$2.53 Billion ≈ $79.59 Million |
+7.68pp |
| 2006-12-31 | 16.18% | NT$402.00 Million ≈ $12.67 Million |
NT$2.48 Billion ≈ $78.28 Million |
-6.33pp |
| 2005-12-31 | 22.51% | NT$533.12 Million ≈ $16.80 Million |
NT$2.37 Billion ≈ $74.61 Million |
+8.51pp |
| 2004-12-31 | 14.00% | NT$343.66 Million ≈ $10.83 Million |
NT$2.45 Billion ≈ $77.34 Million |
+6.00pp |
| 2003-12-31 | 8.00% | NT$184.75 Million ≈ $5.82 Million |
NT$2.31 Billion ≈ $72.78 Million |
+4.12pp |
| 2002-12-31 | 3.87% | NT$96.18 Million ≈ $3.03 Million |
NT$2.48 Billion ≈ $78.21 Million |
-- |
About Grape King Bio Ltd
Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company provides health products and supplements; a… Read more